专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2692719A1 Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof 有权
标题翻译：一种用于肌酸脂肪酯的制备方法，由此制备的肌酸脂肪酯及其用途
公开(公告)号：EP2692719A1
公开(公告)日：2014-02-05
申请号：EP12352002.5
申请日：2012-07-30
申请人： Commissariat à l'Énergie Atomique et aux Énergies Alternatives
发明人： Dezard, Sophie , Taran, Frédéric , Trotier-Fauron, Alexandra , Mabondzo, Aloise
IPC分类号： C07C277/08 , C07C279/14 , C07C279/20 , C07H13/04 , A23L1/305 , A61K31/22 , A61K31/7024 , A61P21/00 , A61P25/16 , A61P9/00 , A61P29/00 , A61P25/00 , A61Q19/00
CPC分类号： C07C279/14 , A23L33/175 , A23V2002/00 , C07C277/08 , C07D233/88 , C07C279/24
摘要： The present invention concerns a method for preparing a creatine fatty ester or derivative thereof comprising at least one step consisting in reacting a diprotected creatinine with a molecule bearing at least one alcohol functional group and of formula R'-OH in which R' represents a hydrocarbon radical containing at least 4 carbon atoms. The present invention also concerns particular creatine fatty esters or derivative thereof and medical uses thereof.
摘要翻译：本发明涉及一种用于制备肌酸脂肪酸酯或它们的衍生物，包括至少一个步骤中反应的双保护的肌酸酐与分子带有至少一个醇官能团和式R'-OH，其中R“darstellt烃由......组成团，其含有至少四个碳原子。因此，本发明涉及的特殊肌酸脂肪酸酯或它们的衍生物以及它们的医疗用途。

2. 发明公开

EP2061754A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS 审中-公开
标题翻译：联芳和二杂芳基化合物铁代谢紊乱的治疗
公开(公告)号：EP2061754A1
公开(公告)日：2009-05-27
申请号：EP08744072.3
申请日：2008-03-19
申请人： Xenon Pharmaceuticals Inc.
发明人： CHAFEEV, Mikhail , CHAKKA, Nagasree , CADIEUX, Jean-Jacques , FU, Jianmin , KAMBOJ, Rajender , KODUMURU, Vishnumurthy , LANGILLE, Jonathan , LIU, Shifeng , SUN, Jianyu , SVIRIDOV, Serguei , ZHANG, Zaihui
IPC分类号： C07C279/20 , C07C279/28 , C07C317/42 , C07C323/43 , C07D333/34 , A61K31/155 , A61K31/381 , A61P7/00
CPC分类号： C07D333/34 , C07C323/44 , C07C323/62 , C07C335/16 , C07C335/32 , C07D333/38
摘要： This invention is directed to compounds of formula (I), wherein A, B, m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

4. 发明公开

EP0921117A2 Acylguanidine 失效
标题翻译：酰基胍
公开(公告)号：EP0921117A2
公开(公告)日：1999-06-09
申请号：EP99102583.4
申请日：1994-08-18
申请人： HOECHST AKTIENGESELLSCHAFT
发明人： Kleemann, Heinz-Werner Dr. , Lang, Hans-Jochen Dr. , Weichert, Andreas Dr. , Crause, Peter Dr. , Scholz, Wolfgang Dr. , Albus, Udo Dr. , Schwark, Jan-Robert Dr.
IPC分类号： C07C279/20 , C07C279/22
CPC分类号： C07D295/155 , C07C279/22 , C07C317/44 , C07C2601/04 , C07C2601/08 , C07D215/54 , C07D231/12 , C07D233/56 , C07D249/08
摘要： Guanidin-Verbindungen der Formel III
mit X(2) mit den in den Ansprüchen angegebenen Bedeutungen dienen zum Herstellen von wertvollen antiarrhythmischen Arzneimitteln mit cardioprotektiver Komponente zur Infarktprophylaxe und der Infarktbehandlung sowie zur Behandlung der angina pectoris hervorragend geeignet, wobei sie auch präventiv die pathophysiologischen Vorgänge beim Entstehen ischämisch induzierter Schäden, insbesondere bei der Auslösung ischämisch induzierter Herzarrhythmien, inhibieren oder stark vermindern. Wegen deren schützender Wirkungen gegen pathologische hypoxische und ischämische Situationen können diese Verbindungen infolge Inhibition des zellulären Na + /H + -Austauschmechanismus als Arzneimittel zur Behandlung aller akuten oder chronischen durch Ischämie ausgelösten Schäden oder dadurch primär oder sekundär induzierten Krankheiten verwendet werden.
摘要翻译：苯甲酰基胍衍生物（III）是新的。（III）具有式X2-CO-N = C（NH 2）2 X 2 = R 101 =氢，氟，氯，羟基，氨基或三氟甲基; R 102 =氢，氟，氯，溴，氰基，CqF2qCF3，R13SO2，R14R15NCO，R16CO或R17R18NSO2; R13，R14，R16和R17 = 1-8C烷基，3-4C烯基，C nH2n-R20，三氟甲基或除R13以外的氢; n = 0或1; q = 1-5; R 20 = 3-6C环烷基或苯基，任选被1-2的氟，氯，三氟甲基，甲基，甲氧基或NR 21 R 22取代; R21和R22 =氢或甲基; R 104 = 1-8C烷基，C n H 2n R 20，三氟甲基，（异）喹啉基，吡咯基，吡啶基或咪唑基（所有这些环通过碳或氮键合并任选被1或2个氟，氯，三氟甲基，甲氧基，羟基或氨基被1或2个甲基取代）），R87SO2，R88R89NSO2或R93-乙炔基; R87 = 1-4C烷基或三氟甲基; R 88 =氢，1-4C烷基，三氟甲基或（CH 2）a R 90; a = 0或1; R 90和R 93 =如R 20中任选取代的苯基; R103 =任何一个宽范围的取代基。完整定义在定义（完全定义）字段中给出。

5. 发明公开

EP3190209A1 1-ACYLGUANIDINE COMPOUNDS AND THE USE OF SAID COMPOUNDS IN ELECTROLESS DEPOSITION OF NICKEL AND NICKEL ALLOY COATINGS 有权
标题翻译： 1-乙酰胍类化合物及其在化学镀镍镍合金涂层中的应用
公开(公告)号：EP3190209A1
公开(公告)日：2017-07-12
申请号：EP16150308.1
申请日：2016-01-06
申请人： Atotech Deutschland GmbH
发明人： Brunner, Dr. Heiko , Pape, Simon , Bejan, Dr. Iulia
IPC分类号： C23C18/34 , C23C18/36 , C07C279/20
CPC分类号： C23C18/34 , C07C309/15 , C07C309/51 , C23C18/36
摘要： The invention relates to an aqueous plating bath composition for electroless deposition of nickel or a nickel alloy, the composition comprising: (i) a source of nickel ions, wherein the aqueous plating bath composition further comprises (ii) at least one accelerating compound which is a 1-acylguanidine compound having general chemical formula I, wherein R 1 is selected from the group comprising alkyl and aryl; R 2 is a radical having general chemical formula -R 4 -SO 3 M, wherein R 4 is selected from the group comprising alkylene and arylene; wherein M is hydrogen or a metal atom or any other cation forming radical having a valency of one or is an M th fraction of a metal atom or any other cation forming radical having a valency of m, wherein m is 2 or 3; R 3 is selected from the group comprising -Hal, -OR 5 , and -NR 5 R 6 , wherein R 5 , R 6 are independently selected from the group comprising hydrogen, alkyl and aryl; and n is an integer ranging from 1 to 5.
摘要翻译：本发明涉及一种用于镍或镍合金的无电沉积的水性镀浴组合物，该组合物包含：（i）镍离子源，其中该水性镀浴组合物还包含（ii）至少一种加速化合物，其为具有化学通式I的1-酰基胍化合物，其中R 1选自烷基和芳基; R2是具有化学通式-R4-SO3M的基团，其中R4选自亚烷基和亚芳基; 其中M是氢或金属原子或任何其他形成具有一价化合价的基团的阳离子，或者是金属原子或任何其他形成具有化合价的基团的阳离子的M级分，其中m是2或3; R 3选自-Hal，-OR 5和-NR 5 R 6，其中R 5，R 6独立地选自氢，烷基和芳基; 并且n是从1到5的整数。

6. 发明授权

EP1041980B1 ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD 有权
标题翻译：酰基胍钠/质子交换抑制剂
公开(公告)号：EP1041980B1
公开(公告)日：2005-02-23
申请号：EP98961926.7
申请日：1998-12-04
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： AHMAD, Saleem , WU, Shung, C. , ATWAL, Karnail, S. , DUGAR, Sundeep
IPC分类号： A61K31/33 , A61K31/34 , A61K31/36 , A61K31/38 , A61K31/40 , A61K31/41 , A61K31/42 , A61K31/44 , A61K31/55 , A61K31/155 , A61K31/165 , A61K31/335 , A61K31/395 , A61K31/415 , A61K31/435 , A61K31/445 , C07C279/02 , C07C279/16 , C07C279/18 , C07C279/20
CPC分类号： C07D207/327 , C07C279/22 , C07C2601/02 , C07C2602/42 , C07D207/16 , C07D213/56 , C07D213/61 , C07D213/64 , C07D231/12 , C07D233/56 , C07D233/64 , C07D249/08 , C07D271/12 , C07D307/79 , C07D307/81 , C07D311/58 , C07D317/60 , C07D317/62 , C07D409/10 , C07D413/04
摘要： Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have structure (I) wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R?1, R2, R3 and R4¿ are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.

7. 发明公开

EP1104304A1 MULTIVALENT AVB3 AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS 审中-公开
标题翻译：多价配体avB3和转移相关的接收DOORS
公开(公告)号：EP1104304A1
公开(公告)日：2001-06-06
申请号：EP99916118.5
申请日：1999-04-07
申请人： G.D. SEARLE & CO.
发明人： FOK, Kam, F. , TJOENG, Foe, S.
IPC分类号： A61K38/00 , C07C279/18 , C07C279/20
CPC分类号： A61K47/6425 , A61K47/642
摘要： The present invention relates to pharmaceutical compounds which are multivalent avb3 receptor/metastasis-associated receptor ligands. The use of these multivalent ligands alone or in conjunction with other agents in pharmaceutical compositions, and in methods for treating conditions mediated by avb3 for the treatment of cancer and other angiogenic diseases, such as diabetic retinopathy, arthritis, hemangiomas, and psoriasis, are also disclosed.

8. 发明授权

EP0640587B1 Diacylsubstituierte Guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament 失效
标题翻译：二酰基取代的胍，它们的制备，它们作为药物或诊断用途，和药物含有它们的方法
公开(公告)号：EP0640587B1
公开(公告)日：1999-12-29
申请号：EP94112895.1
申请日：1994-08-18
申请人： HOECHST AKTIENGESELLSCHAFT
发明人： Kleemann, Heinz-Werner Dr. , Lang, Hans-Jochen Dr. , Weichert, Andreas Dr. , Crause, Peter Dr. , Scholz, Wolfgang Dr. , Albus, Udo Dr. , Schwark, Jan-Robert Dr.
IPC分类号： C07C279/20 , C07C279/22 , A61K31/155 , C07D231/12 , C07D295/155 , C07D207/327
CPC分类号： C07D295/155 , C07C279/22 , C07C317/44 , C07C2601/04 , C07C2601/08 , C07D215/54 , C07D231/12 , C07D233/56 , C07D249/08

9. 发明公开

EP0685457A4 GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION. 失效
标题翻译：甘油的衍生物，设备和药物组合物。
公开(公告)号：EP0685457A4
公开(公告)日：1996-09-18
申请号：EP94907060
申请日：1994-02-17
申请人： NIPPON SHINYAKU CO LTD
发明人： YANO JUNICHI , OHGI TADAAKI
IPC分类号： A61K31/70 , A61K9/127 , A61K9/52 , A61K9/66 , A61K47/10 , A61K47/24 , A61K47/44 , C07C229/06 , C07C229/12 , C07C237/08 , C07C271/16 , C07C271/20 , C07C279/04 , C07C279/20 , C07C307/02 , C07C333/04 , C07D207/08 , C07D211/08 , C07D241/04 , C07D265/30 , C07D295/13 , C07F9/40
CPC分类号： A61K31/70 , A61K9/1272 , C07C229/12 , C07C237/08 , C07C271/16 , C07C271/20 , C07C279/20 , C07C333/04 , C07D295/13 , C07F9/4075
摘要： The invention aims at providing a device comprising lipids that act like the so-called cationic liposome and are reduced in toxicity and the lipids as the constituent of the device. The invention compounds are exemplified by 3-0-(4-dimethylaminobutanoyl)-1,2-0-dioleylglycerol, 3-0-(2-dimethylaminoethyl)carbamoyl-1,2-0-dioleylglycerol, 3-0-(2-diethylaminoethyl)carbamoyl-1,2-0-dioleylglycerol, and 2-0-(2-diethylaminoethyl)-carbamoyl-1,3-0-dioleylglycerol. The device comprises these lipids and phospholipids. The device enables, when administered together with, for example, a double-stranded RNA, the RNA to migrate to the action site safely.

10. 发明公开

EP0644181A4 AMINO ACID DERIVATIVE AND USE THEREOF. 失效
标题翻译：氨基衍生物UNE用途。
公开(公告)号：EP0644181A4
公开(公告)日：1995-07-05
申请号：EP93910424
申请日：1993-06-01
申请人： FUJI PHOTO FILM CO LTD
发明人： NISHIKAWA NAOYUKI , ORIKASA ATSUSHI , KOMAZAWA HIROYUKI , KOJIMA MASAYOSHI , SAIKI IKUO-NISHI-CHOME , AZUMA ICHIRO
IPC分类号： A61K31/195 , A61K31/22 , A61K38/00 , A61P35/00 , A61P43/00 , C07C233/47 , C07C237/12 , C07C279/14 , C07C279/20 , C07D251/52 , C07K5/02 , C07K5/06 , C07K5/072 , C07C237/22
CPC分类号： C07K5/06095 , A61K38/00 , C07C233/47 , C07C279/14 , C07D251/52 , C07K5/0202 , C07K5/0205 , C07K5/0215 , C07K5/06113
摘要： An amino acid derivative represented by general formula (I), a pharmacologically acceptable salt thereof, and a cancer metastasis inhibitor containing the same, wherein L?1 and L2¿ represent each an amino acid residue, etc.; A?1 and A3¿ represent each C=O; A2 represents alkylene, etc.; m and n represent each an integer of 1 to 5; V represents -NHC(=NH)NH¿2?, etc.; W represents -COOH, etc.; R?1 and R2¿ represent each hydrogen, alkyl, etc.; R?3 and R4¿ represent each hydrogen, etc.; and X and Y represent each -NH- or -O-. The derivative has a potent effect of inhibiting cancer metastasis and is reduced in the activity of inhibiting platelet agglutination and the anticoagulant activity.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式